Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Nrf2 activator
Sulforaphane in Clinical Medicine: A Decade of Research Progress and Therapeutic Potential
Posted inCardiology Diabetes & Endocrinology Neurology news Specialties

Sulforaphane in Clinical Medicine: A Decade of Research Progress and Therapeutic Potential

Posted by MedXY By MedXY 08/24/2025
This review synthesizes 10 years of sulforaphane (SFN) research, highlighting its pharmacology, clinical trial outcomes, and emerging therapeutic prospects across cancer, metabolic, renal, neurodevelopmental, and cardiovascular disorders.
Read More
  • Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance
  • Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis
  • MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling
  • Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
  • Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in